Volume 4, Issue 15 (Autumn 2018)                   Caspian.J.Neurol.Sci 2018, 4(15): 184-189 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Janghorbani M, Barzegar M, Mirmosayyeb O, Shaygannejad V. Ischemic Strokes in a Young Woman With Manifestations of Multiple Sclerosis. Caspian.J.Neurol.Sci. 2018; 4 (15) :184-189
URL: http://cjns.gums.ac.ir/article-1-202-en.html
1- Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
2- Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3- Isfahan Neurosciences Research Center, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:   (181 Views)
Background: The current case report aimed at describing the clinical, radiological, and immunological findings of a case of ischemic stroke due to acute thrombosis of the left internal carotid artery and multiple watershed infarctions mimicking Multiple Sclerosis (MS).
Clinical Presentation and Intervention: A 24-year-old right-handed Iranian female was initially diagnosed with Multiple Sclerosis (MS). She presented with weakness in right lower limb. The cerebral Fluid Attenuation Inversion (FLAIR) Magnetic Resonance Imaging (MRI) showed few small and round lesions in deep white matter, semi-oval centrums, paraventricular region, and subcortical region on left hemisphere. MS was suspected. The patient’s neurological status worsened, after four days she presented hemi-paresis, dysarthria, and hemi-facial paresis. The cerebral Diffusion-Weighted (DW)-MRI, Apparent Diffusion Coefficient (ADC), Duplex Scan (DS), Complete Blood Count (CBC), coagulation, blood chemistry, blood lipids, and autoimmune and immunodiagnostic pathology were performed. Test for Anti-double stain DNA (dsDNA), IgG anti-cardiolipin antibodies, and lupus anticoagulant were positive. DNA bound lactoferrin, anti-Sm antibodies, Anti-Sjögren’s-Syndrome-related Antigen (Anti-SSA) autoantibodies, IgM anti-cardiolipin antibodies, and Anti-beta-2 glycoprotein-1 (IgMIgG) were negative. Ischemic stroke due to acute thrombosis of the left internal carotid artery and multiple watershed infarctions were confirmed in the patient. Heparin and then warfarin therapy was started. At that time she was treated with warfarin, hydroxychloroquine (200 mg/d) and atorvastatin (20 mg/d). The outcome was favorable. 
Conclusion: The current case presented with clinically susceptible symptoms of MS, but had a stroke. Therefore, stroke in young patients can mimic MS symptoms.
Full-Text [PDF 1006 kb]   (71 Downloads) |   |   Full-Text (HTML)  (35 Views)  
Type of Study: case report | Subject: Special
Received: 2018/01/5 | Accepted: 2018/06/13 | Published: 2018/10/1

References
1. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple Sclerosis in Sweden. Mult Scler J. 2011; 17(8):901-8.[DOI:10.1177/1352458511403794] [PMID] [DOI:10.1177/1352458511403794]
2. Milo R, Kahana E. Multiple Sclerosis: Geoepidemiology, genetics and the environment. Autoimmun Rev. 2010; 9(5):A387-94. [DOI:10.1016/j.autrev.2009.11.010] [PMID] [DOI:10.1016/j.autrev.2009.11.010]
3. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple Sclerosis. J Neuroimmunol. 2007; 184(1-2):37-44. [DOI:10.1016/j.jneuroim.2006.11.015] [PMID] [PMCID] [DOI:10.1016/j.jneuroim.2006.11.015]
4. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple Sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. [DOI:10.1002/ana.22366] [PMID] [PMCID] [DOI:10.1002/ana.22366]
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple Sclerosis: Guidelines from the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol. 2001; 50(1):121-27. [DOI:10.1002/ana.1032] [PMID] [DOI:10.1002/ana.1032]
6. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple Sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. [DOI:10.1002/ana.20703] [PMID] [DOI:10.1002/ana.20703]
7. De Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest. 2010; 40(9):835-42. [DOI:10.1111/j.1365-2362.2010.02333.x] [PMID] [DOI:10.1111/j.1365-2362.2010.02333.x]
8. Kramer HR, Giles JT. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res. 2011; 63(4):484-99. [DOI:10.1002/acr.20386] [PMID] [DOI:10.1002/acr.20386]
9. Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease-risk factors and outcomes: A systematic review of the literature. Arthritis Care Res. 2011; 26(9):1036-49. [DOI:10.1007/s11606-011-1698-5] [PMID] [PMCID] [DOI:10.1007/s11606-011-1698-5]
10. De Simone C, Di Giorgio A, Sisto T, Carbone A, Ghitti F, Tondi P, et al. Endothelial dysfunction in psoriasis patients: Cross-sectional case-control study. Eur J Dermatol. 2011; 21(4):510-4. [PMID] [PMID]
11. Huck O, Saadi Thiers K, Tenenbaum H, Davideau JL, Romagna C, Laurent Y, et al. Evaluating periodontal risk for patients at risk of or suffering from atherosclerosis: Recent biological hypotheses and therapeutic consequences. Arch Cardiovasc Dis. 2011; 104(5):352-8. [DOI:10.1016/j.acvd.2011.02.002] [PMID] [DOI:10.1016/j.acvd.2011.02.002]
12. Beukers NG, Van Der Heijden GJ, Van Wijk AJ, Loos BG. Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60 174 participants in a large dental school in the Netherlands. BMJ. 2017; 71; 37-42.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. [DOI:10.1056/NEJM199901143400207] [PMID] [DOI:10.1056/NEJM199901143400207]
14. Weill C, Suissa L, Darcourt J, Mahagne MH. The pathophysiology of watershed infarction: A three-dimensional time-of-flight magnetic resonance angiography study. J Stroke Cerebrovasc Dis. 2017; 26(9):1966-73. [DOI:10.1016/j.jstrokecerebrovasdis.2017.06.016] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2017.06.016]
15. Maki T, Wakita H, Mase M, Itagaki I, Saito N, Ono F, et al. Watershed infarcts in a multiple microembolic model of monkey. Neurosci Lett. 2011; 499(2):80-3. [DOI:10.1016/j.neulet.2011.05.036] [PMID] [DOI:10.1016/j.neulet.2011.05.036]
16. Rosso C, Remy P, Creange A, Brugieres P, Cesaro P, Hosseini H. Diffusion-weighted MR imaging characteristics of acute stroke like form of multiple Sclerosis. AJNR Am J Neuroradiol. 2006; 27(5):1006-8. [PMID] [PMID]
17. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple Sclerosis. Mult Scler J. 2013; 19(10):1336-40. [DOI:10.1177/1352458513475833] [PMID] [DOI:10.1177/1352458513475833]
18. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple Sclerosis: A population-based cohort study. Neuroepidemiology. 2010; 35(4):267-74. [DOI:10.1159/000320245] [PMID] [DOI:10.1159/000320245]
19. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple Sclerosis. Mult Scler J. 2015; 21(3):318-31. [DOI:10.1177/1352458514564490] [PMID] [PMCID] [DOI:10.1177/1352458514564490]
20. Tseng CH, Huang WS, Lin CL, Chang YJ. Increased risk of ischemic stroke among patients with multiple Sclerosis. Eur J Neurol. 2015; 22(3):500-6. [DOI:10.1111/ene.12598] [DOI:10.1111/ene.12598]
21. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008; 371(9624):1612-23. [DOI:10.1016/S0140-6736(08)60694-7] [DOI:10.1016/S0140-6736(08)60694-7]
22. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42(2):517-84. [DOI:10.1161/STR.0b013e3181fcb238] [PMID] [DOI:10.1161/STR.0b013e3181fcb238]
23. The American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010; 121(7):e46-e215. [PMID] [PMID]
24. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L. Long-term risk factors for stroke: Twenty-eight years of follow-up of 7457 middle-aged men in Göteborg, Sweden. Stroke. 2006; 37(7):1663-7. [DOI:10.1161/01.STR.0000226604.10877.fc] [PMID] [DOI:10.1161/01.STR.0000226604.10877.fc]
25. Haas LF. Stroke as an early manifestation of systemic lupus erythematosus. Journal of Neurology, Neurosurgery & Psychiatry. 1982; 45(6):554-6. [DOI:10.1136/jnnp.45.6.554] [PMID] [PMCID] [DOI:10.1136/jnnp.45.6.554]
26. Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thrombosis and Haemostasis. 2009; 101(1):100-7. [DOI:10.1160/TH08-06-0384] [PMID] [PMCID] [DOI:10.1160/TH08-06-0384]
27. Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: A consensus report. Lupus. 2011; 20(2):153-7. [DOI:10.1177/0961203310396748] [PMID] [DOI:10.1177/0961203310396748]
28. Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology. 1999; 28(6):344-51. [DOI:10.1080/03009749950155320] [PMID] [DOI:10.1080/03009749950155320]
29. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus. 2003; 12(4):302-7. [DOI:10.1191/0961203303lu339oa] [PMID] [DOI:10.1191/0961203303lu339oa]
30. Alarc N, Segovia D, Deleze M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Med. 1989; 68(6):353–65. [DOI:10.1097/00005792-198911000-00003] [DOI:10.1097/00005792-198911000-00003]
31. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in Systemic Lupus Erythematosus (SLE) and in non SLE disorders. Ann Intern Med. 1990; 112(9):682–98. [DOI:10.7326/0003-4819-112-9-682] [PMID] [DOI:10.7326/0003-4819-112-9-682]
32. Remondino G, Allevi A. Antiphospholipid antibodies and autoimmune diseases. Open Autoimmun J. 2010; 2:38-44. [DOI:10.2174/1876894601002020038] [DOI:10.2174/1876894601002020038]
33. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus. 2007; 16(5):324-9. [DOI:10.1177/0961203307077993] [PMID] [DOI:10.1177/0961203307077993]
34. Tanasescu R, Nicolau A, Ticmeanu M, Cojocaru I, Ene A, Caraiola S, et al. Headache, antiphospholipid antibodies and cerebral ischemia in patients with systemic immune-mediated diseases. Rom J Neurol. 2007; 6(2):71-108.

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2017 All Rights Reserved | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb